Approval · Notice of Compliance 27744 · 2022
ZYMAR: Notice of Compliance 27744
Issued March 11, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27744
- Date
- March 11, 2022
- Company
- Allergan IncMarkham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph (PM) to the 2020 format, and to update the labels to meet Plain Language Labelling (PLL) requirements.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZYMAR | Not yet assigned | — |
Medicinal ingredients
- GATIFLOXACIN 0.3 PER